Skip to main content

Table 2 Correlation between clinical features and H-SCORE of IHC based on the tissue microarray

From: Identification of ZBTB9 as a potential therapeutic target against dysregulation of tumor cells proliferation and a novel biomarker in Liver Hepatocellular Carcinoma

Characteristic

Low scores (n = 39)

High scores (n = 40)

p. value

No. (%)

No. (%)

Gender, n (%)

  

0.511

 Female

8 (10.1%)

5 (6.3%)

 

 Male

31 (39.2%)

35 (44.3%)

 

T stage, n (%)

  

0.039

 T1a

13 (16.5%)

5 (6.3%)

 

 T1b

12 (15.2%)

12 (15.2%)

 

 T2

13 (16.5%)

16 (20.3%)

 

 T3

1 (1.3%)

7 (8.9%)

 

N stage, n (%)

  

0.615

 N0

37 (46.8%)

39 (49.4%)

 

 N1

2 (2.5%)

1 (1.3%)

 

M status, n (%)

  

0.066

 M0

37 (46.8%)

31 (39.2%)

 

 M1

2 (2.5%)

8 (10.1%)

 

 M2

0 (0%)

1 (1.3%)

 

HBsAg, n (%)

  

0.953

 Negative

9 (11.4%)

8 (10.1%)

 

 Positive

30 (38%)

32 (40.5%)

 

HBcAb, n (%)

  

1.000

 Negative

7 (8.9%)

7 (8.9%)

 

 Positive

32 (40.5%)

33 (41.8%)

 

Age, mean ± SD

53.82 ± 9.37

50.38 ± 12.66

0.173